ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,631.22
      0.28%
      US Tech 100
      19,846.00
      0.00%
      Dow Jones
      40,211.72
      0.53%
      Brent Oil
      83.68
      -0.78%
      Bitcoin
      63,043.27
      -2.79%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. IDEAYA Biosciences Inc (IDYA)

      7. IDEAYA Biosciences Inc (IDYA) News

      IDYA

      IDEAYA Biosciences (IDYA)

      IDEAYA Biosciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IDYA
      DateTimeSourceHeadlineSymbolCompany
      10/06/20236:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
      09/27/20236:43AMDow Jones NewsIDEAYA Biosciences Gets Fast-Track Designation for IDE161 for Breast CancerNASDAQ:IDYAIDEAYA Biosciences Inc
      09/27/20236:00AMPR Newswire (US)IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast CancerNASDAQ:IDYAIDEAYA Biosciences Inc
      09/26/20236:42AMDow Jones NewsIDEAYA Biosciences Gets FDA Fast-Track Designation for IDE161 in Ovarian CancerNASDAQ:IDYAIDEAYA Biosciences Inc
      09/26/20236:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      09/26/20236:00AMPR Newswire (US)IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 MutationsNASDAQ:IDYAIDEAYA Biosciences Inc
      09/14/20235:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      09/11/20236:00AMPR Newswire (US)IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
      09/06/20236:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      09/06/20236:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      09/05/20236:00AMPR Newswire (US)IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
      09/01/20236:21PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/31/20235:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/23/20236:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/21/20236:00AMPR Newswire (US)IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)NASDAQ:IDYAIDEAYA Biosciences Inc
      08/18/20236:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/16/20236:00AMPR Newswire (US)IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
      08/11/20237:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/11/20237:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/10/20234:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
      08/10/20236:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      08/10/20236:00AMPR Newswire (US)IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
      08/09/20234:43PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      08/02/20236:00AMPR Newswire (US)IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
      08/01/20236:00AMPR Newswire (US)IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
      07/28/20236:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
      07/12/20235:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      07/10/20234:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      07/03/20237:50PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      07/03/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
       Showing the most relevant articles for your search:NASDAQ:IDYA

      Your Recent History

      NASDAQ
      TETEW
      Technology and Telecommu...
      Delayed Upgrade Clock